These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23653011)

  • 21. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
    MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
    Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should ACE inhibitors and ARBs be used in combination in children?
    Stotter BR; Ferguson MA
    Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel effective drugs for diabetic kidney disease? or not?
    Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA
    Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.
    El-Haddad B; Reule S; Drawz PE
    Curr Diab Rep; 2015 Oct; 15(10):70. PubMed ID: 26275442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.
    Perico N; Ruggenenti P; Remuzzi G
    Curr Opin Pharmacol; 2017 Apr; 33():34-40. PubMed ID: 28482281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease.
    Jiang S; Fang J; Yu T; Li W
    Eur J Intern Med; 2021 Mar; 85():127-129. PubMed ID: 33250340
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
    Alsaeed A
    Saudi Med J; 2021 Jan; 42(1):115. PubMed ID: 33399181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Eberhard R; Dikow R
    Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update of the blockade of the renin angiotensin aldosterone system in clinical practice.
    Márquez DF; Ruiz-Hurtado G; Ruilope LM; Segura J
    Expert Opin Pharmacother; 2015; 16(15):2283-92. PubMed ID: 26389772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of aldosterone antagonism agents in diabetic kidney disease.
    Wombwell E; Naglich A
    J Ren Care; 2015 Mar; 41(1):9-18. PubMed ID: 25220494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.